Literature DB >> 21151205

Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Anas Younes1.   

Abstract

An improved understanding of the molecular biology of cancer cell growth and survival and the role of the microenvironment in supporting the survival of cancer cells, including lymphoma cells, has led to the identification of a number of potential therapeutic targets. Despite these advances, drug development for lymphoma remains slow, inefficient, and frequently unfocused. Future work should focus on identifying 'driver' molecular defects of oncogenic pathways that can be targeted therapeutically, discovering predictive biomarkers for treatment response, and prioritizing promising drugs to accelerate their approval. This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21151205      PMCID： PMC3192435          DOI： 10.1038/nrclinonc.2010.189

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  89 in total

Review 1.  PI3K/Akt: getting it right matters.

Authors:  T F Franke
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

2.  Focus Issue: demystifying mTOR signaling.

Authors:  Nancy R Gough
Journal:  Sci Signal       Date:  2009-04-21       Impact factor: 8.192

3.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 4.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

5.  Cancer occurrence.

Authors:  Ahmedin Jemal; Melissa M Center; Elizabeth Ward; Michael J Thun
Journal:  Methods Mol Biol       Date:  2009

Review 6.  Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

Review 7.  The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.

Authors:  S Wang
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

Review 8.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

Review 9.  BRAF signaling and targeted therapies in melanoma.

Authors:  Nathalie Dhomen; Richard Marais
Journal:  Hematol Oncol Clin North Am       Date:  2009-06       Impact factor: 3.722

10.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Authors:  Anthony W Tolcher; Alain Mita; Lionel D Lewis; Christopher R Garrett; Elizabeth Till; Adil I Daud; Amita Patnaik; Kyri Papadopoulos; Chris Takimoto; Pamela Bartels; Anne Keating; Scott Antonia
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 50.717
View more
  29 in total

1.  Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Authors:  Anas Younes; Yasuhiro Oki; Peter McLaughlin; Amanda R Copeland; Andre Goy; Barbara Pro; Lei Feng; Ying Yuan; Hubert H Chuang; Homer A Macapinlac; Fredrick Hagemeister; Jorge Romaguera; Felipe Samaniego; Michelle A Fanale; Bouthaina Shbib Dabaja; Maria A Rodriguez; Nam Dang; Larry W Kwak; Sattva S Neelapu; Luis E Fayad
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

3.  Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.

Authors:  Bing Xia; Fulian Qu; Tian Yuan; Yizhuo Zhang
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

4.  Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Authors:  Carmelo Carlo-Stella; Francesca Ricci; Serena Dalto; Rita Mazza; Michele Malagola; Francesca Patriarca; Simonetta Viviani; Domenico Russo; Laura Giordano; Luca Castagna; Paolo Corradini; Armando Santoro
Journal:  Oncologist       Date:  2015-02-10

Review 5.  Precision therapy for lymphoma--current state and future directions.

Authors:  Andrew M Intlekofer; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2014-08-19       Impact factor: 66.675

6.  Measurement science in the circulatory system.

Authors:  Casey M Jones; Sandra M Baker-Groberg; Flor A Cianchetti; Jeremy J Glynn; Laura D Healy; Wai Yan Lam; Jonathan W Nelson; Diana C Parrish; Kevin G Phillips; Devon E Scott-Drechsel; Ian J Tagge; Jaime E Zelaya; Monica T Hinds; Owen J T McCarty
Journal:  Cell Mol Bioeng       Date:  2014-03       Impact factor: 2.321

7.  BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Authors:  S L Locatelli; L Cleris; G G Stirparo; S Tartari; E Saba; M Pierdominici; W Malorni; A Carbone; A Anichini; C Carlo-Stella
Journal:  Leukemia       Date:  2014-02-24       Impact factor: 11.528

8.  Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.

Authors:  Yasuhiro Oki; Daniela Buglio; Michelle Fanale; Luis Fayad; Amanda Copeland; Jorge Romaguera; Larry W Kwak; Barbara Pro; Silvana de Castro Faria; Sattva Neelapu; Nathan Fowler; Fredrick Hagemeister; Jiexin Zhang; Shouhao Zhou; Lei Feng; Anas Younes
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

Review 9.  Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

Authors:  N Epperla; T S Fenske; H M Lazarus; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-08-17       Impact factor: 5.483

10.  Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.

Authors:  Beata Holkova; Maciej Kmieciak; Prithviraj Bose; Victor Y Yazbeck; Paul M Barr; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; April D Rollins; Erin M Cebula; Emily Pierce; Megan Herr; Heidi Sankala; Kevin T Hogan; Wen Wan; Changyong Feng; Derick R Peterson; Richard I Fisher; Steven Grant; Jonathan W Friedberg
Journal:  Leuk Lymphoma       Date:  2015-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.